Intervention

UBT251

ClinicalTrials.gov intervention label

Clinical trials8

Recruiting6

Common conditions9

Lead sponsors shown2

Clinical trials

8 shown

A Research Study Looking Into How UBT251 Works With Birth Control Tablets and Emptying of the Stomach in Women With Excess Body Weight Not Able to Become PregnantNCT07710729 · 2026-07-17

A Research Study on How UBT251 Affects Levels of Midazolam, Caffeine and Warfarin in the Blood of Participants With Excess Body WeightNCT07710768 · 2026-07-15

A Research Study Comparing How Well Different Doses of the Medicine UBT251 Lower Blood Sugar in People With Type 2 DiabetesNCT07668388 · 2026-06-22

Phase I Drug-Drug Interaction Study of UBT251 Injection in Participants With Overweight or ObesityNCT07785934 · 2026-05-27

A Research Study on How Well Different Doses of the Medicine UBT251 Help People Living With Overweight or ObesityNCT07395687 · 2026-02-02

UBT251 Injection Phase II Clinical Study (CKD)NCT07134335 · 2025-09-01

UBT251 Injection Phase Ⅲ Study (OSA-PAP)NCT07806851 · 2026-10-10

NOT_YET_RECRUITING

UBT251 Injection Phase Ⅲ Study (OSA-NPAP)NCT07767942 · 2026-09-18

NOT_YET_RECRUITING

Common conditions

Obesity4 Overweight3 Chronic Kidney Disease1 Diabetes Mellitus, Type 21 Drug Drug Interaction (DDI)1 Obesity &Amp; Overweight1 Obstructive Sleep Apnea1 Obstructive Sleep Apnea, Obesity1 Pharmacokinetics and Pharmacodynamics1

Leading sponsors

Novo Nordisk A/S4 The United Bio-Technology (Hengqin) Co., Ltd.4

Trial status mix

RECRUITING6

NOT_YET_RECRUITING2

Phase mix

PHASE13

PHASE23

PHASE32

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.